Alexander C. Schultz

Alexander C. Schultz

Auto-generated profile, based on publicly available information

Alexander C. Schultz

Microbiology and Cell Science Department, Institute of Food and Agricultural Sciences, University of Florida

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Journal of Applied Microbiology
Verified
Journal Article
Closed access
DCDavid J. Culp
David J. Culp
WHWilliam Hull
William Hull
ASAlexander C. Schultz
Alexander C. Schultz
ABAshley S. Bryant
Ashley S. Bryant
CLClaudia A. Lizarraga
Claudia A. Lizarraga
RBRobert A. Burne
Robert A. Burne

8 October 2025 in mBio
Verified
Journal Article
Open access
JSJohn Santelices
John Santelices
ASAlexander Schultz
Alexander Schultz
AWAlyssa Walker
Alyssa Walker
NANicole Adams
Nicole Adams
DTDeyaneira Tirado
Deyaneira Tirado
Mariola EdelmannMariola Edelmann
Mariola Edelmann
The rise of antibiotic-resistant bacterial pathogens poses a critical global health challenge, necessitating innovative therapeutic strategies. This study explores host-targeted therapies by focusing on deubiquitinating enzymes (DUBs), key regulators of the ubiquitin-proteasome system (UPS) that mediate host-pathogen interactions. Using Salmonella -infected macrophages, we screened a UPS-targeted compound library and identified several compounds that enhanced bacterial clearance without affecting host cell viability. Among these, the dual USP25/USP28 inhibitor AZ-1 emerged as one of the top candidates. Transcriptomic profiling revealed infection-induced upregulation of DUBs, particularly USP25, USP46, and OTUD7B. USP25 knockdown significantly reduced intracellular Salmonella , confirming its role as a critical host factor. AZ-1 also exhibited broad-spectrum intracellular activity against multidrug-resistant Pseudomonas aeruginosa , Klebsiella pneumoniae , and Acinetobacter baumannii . In vivo , AZ-1 reduced fecal bacterial loads, clinical scores, and infection-induced weight loss, though it did not extend survival. AZ-1 had no direct antibacterial activity in axenic culture, indicating a host-targeting mechanism. Transcriptomic and signaling analyses revealed AZ-1 suppressed key immune pathways, including nuclear factor-kappa B (NF-κB) signaling. These findings establish DUBs as promising targets for host-directed therapies and support further development of UPS-targeted agents to combat antimicrobial resistance. IMPORTANCE: Antibiotic-resistant infections, particularly those caused by intracellular pathogens, represent an urgent public health threat due to their ability to evade immune responses and resist conventional antibiotics. This study identifies the ubiquitin-proteasome system, specifically deubiquitinating enzymes, as viable targets for host-directed therapy. We demonstrate that the USP25/USP28 inhibitor AZ-1 enhances intracellular bacterial clearance without compromising host cell viability and is effective against several multidrug-resistant gram-negative pathogens. Knockdown of USP25 alone also reduced intracellular Salmonella , stressing out its proposed role in bacterial persistence. AZ-1 improved early infection outcomes in vivo but was insufficient as monotherapy. These findings support a novel therapeutic approach that targets host pathways to enhance bacterial clearance, offering a promising adjunct to traditional antibiotics in the fight against antimicrobial resistance.

14 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSaloni Bhimani
Saloni Bhimani
ASAlexander C Schultz
Alexander C Schultz
STSae Tanaka
Sae Tanaka
Mariola EdelmannMariola Edelmann
Mariola Edelmann
Small extracellular vesicles (sEVs) released by infected cells carry microbial antigens together with host immunomodulatory molecules, yet whether their structural integrity governs the durability of protective immunity is unknown. Using Salmonella infection as a model, we show that sEVs isolated from infected macrophages act as potent antigen carriers for intranasal immunization. In BALB/c mice, intact sEVs elicited antigen-specific serum IgG responses comparable in magnitude to those induced by live attenuated aroA Salmonella. Immunization further increased fecal IgA binding to Salmonella following lethal challenge and generated serum capable of enhancing macrophage-mediated bacterial uptake. Single-cell RNA sequencing of mesenteric lymph nodes revealed enrichment of mature B cells, effector CD8 T cells, and central memory-like CD4 T cells expressing CD69, CD44, CCR7, and Sell/CD62L, while defined recombinant sEV-associated antigens drove IFN-gamma and IL-2 production by memory T cells ex vivo. Disrupting vesicle architecture by sonication left total IgG and IgG1 induction intact but selectively impaired IgG2a responses and antigen-specific T-cell recall; intact sEVs, by contrast, drove greater dendritic-cell CD80 expression, IL-2 production by cocultured CD69+ CD4 T cells, and prolonged survival after lethal challenge. These findings establish that vesicle integrity is dispensable for the overall magnitude of antibody induction but is required to instruct dendritic-cell costimulation, Th1-associated IgG2a class switching, and durable memory T-cell recall after mucosal immunization, identifying infection-derived sEVs as structurally organized immunogens rather than passive antigen reservoirs.